Publications by authors named "Kristi K DiRocco"
Article Synopsis
- This study examines how well patients with chronic obstructive pulmonary disease (COPD) stick to their medication regimens, comparing a single daily inhaler (FF/UMEC/VI) to a combination that requires two inhalations twice a day (BUD/GLY/FOR).
- Using insurance claims data from 2019 to 2023, researchers evaluated adherence (how often patients take their medication) and persistence (how long they continue treatment), with a total of 11,597 COPD patients involved.
- Results showed that patients using the single inhaler (FF/UMEC/VI) had better adherence and persistence over 6 and 12 months compared to those using the combination
Outcomes Following Initiation of Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol versus Multiple-Inhaler Triple Therapy Among Medicare Advantage with Part D Beneficiaries and Those Commercially Enrolled for Health Care Insurance in the United States.
Michael Bogart Lindsay G S Bengtson Mary G Johnson Scott H Bunner Noelle N Gronroos Kristi K DiRocco
Int J Chron Obstruct Pulmon Dis
January 2024
Purpose: Patients with chronic obstructive pulmonary disease (COPD) have been shown to benefit from triple therapy commonly delivered by multiple-inhaler triple therapy (MITT); however, the complexity of MITT regimens may decrease patient adherence. Fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI), a once-daily single-inhaler triple therapy (SITT), became available in the United States (US) in 2017, but real-world data comparing outcomes for SITT versus MITT are currently limited. This study compared outcomes among patients with COPD initiating MITT versus SITT with FF/UMEC/VI who were either Medicare Advantage with Part D (MAPD) beneficiaries or commercial enrollees in the US.
View Article and Find Full Text PDF